• Explore /
  • Poster
  • / Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts.

Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts.

Abstract Poster

Authors

null

Damian Tobias Rieke

Charité– Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Charité Comprehensive Cancer Center; German Cancer Consortium (DKTK), Berlin, Germany

Damian Tobias Rieke , Till de Bortoli , Manuela Benary , Peter Horak , Mario Lamping , Sebastian Stintzing , Inge Tinhofer , Serge Leyvraz , Reinhold Schäfer , Frederick Klauschen , Ulrich Keller , Albrecht Stenzinger , Stefan Froehling , Razelle Kurzrock , Ivan Jelas , Ulrich Keilholz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Molecular Diagnostics and Imaging

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3066)

DOI

10.1200/JCO.2023.41.16_suppl.3066

Abstract #

3066

Poster Bd #

264

Abstract Disclosures

Similar Posters

First Author: Pasquale Rescigno

First Author: Michael Iglesia

First Author: Guenter Niegisch

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Clinical outcomes for <em>IDH1</em> mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.

Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.

First Author: Darren Cowzer